In the long human struggle against cancer's most stubborn forms, a small injection has offered something rare — genuine surprise. Researchers in London have reported that amivantamab, a bispecific antibody already approved for certain lung cancers, shrank tumors in nearly half of patients whose head and neck cancers had resisted every standard treatment, with fifteen individuals achieving complete remission. Presented to the American Society of Clinical Oncology, the findings arrive as a quiet but significant turning point for a population that had, in the most practical sense, run out of road
thestar.com.my
· May 31, 2026
· health
· 3 min de lectura
High
Verificación: Verificado
Cancer injection eradicates tumours in treatment-resistant cases
Patients with treatment-resistant head and neck cancer experienced significant quality-of-life improvements, including reduced pain, swelling, and elimination of severe chemotherapy side effects.
◉
Health & Medicine
7994 artículos relacionados
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 100% coincidencia
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% coincidencia
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% coincidencia
Researchers identify new Ebola variant, propose repurposed drug treatm…
Medical Xpress · 99% coincidencia
Dalhousie researchers identify new Ebola variant, propose repurposed d…
Education News Canada · 99% coincidencia
Cobertura Relacionada
The Guardian · Aug 18
ADHD diagnosis surge raises questions about identity versus disorder
Experts warn that rising ADHD diagnoses increasingly reflect identity-seeking rather than medical need, with poor-qualit…
BBC News · Aug 18 BBC investigation expands: 30 children feared conceived with wrong donors at Cyprus IVF clinicsAt least 30 children, mostly British, are feared conceived via IVF in northern Cyprus using wrong sperm or egg donors th…
News-Medical · Aug 18 IV Iron Use Among Australian Women Surges 17-Fold in DecadeAustralian women's intravenous iron use jumped 17-fold in a decade, with 1 in 20 reproductive-age women receiving treatm…
geneonline.com · Aug 18 1 in 20 Australian Women Now Receiving IV Iron InfusionsOne in 20 Australian women now receive intravenous iron infusions, marking a significant decade-long increase in this tr…
Sesgo y Encuadre
⚖
Article presents promising cancer treatment results with optimistic framing and expert endorsement, but lacks critical perspective on limitations, side effects, and commercial interests.
Bias Direction
center-right
Confidence
MED
Positive medical breakthrough narrative emphasizing clinical success and patient testimonials, with prominent expert validation and minimal counterbalance on uncertainties or commercial context.
unprecedentedly strong responses
eradicated entire tumours
very striking
potential to benefit many thousands
life-impacting side effects
extremely limited
Cost and accessibility concerns for patients in different healthcare systems
Long-term follow-up data and durability of responses
Comparison with competing treatments in development
Potential adverse effects beyond chemotherapy comparison
Independent analysis not affiliated with trial sponsors
Patient advocacy group perspectives on realistic expectations
Regulatory pathway and timeline to market availability
Johnson & Johnson's commercial interests and pricing strategy
Impacto Geopolítico
🌎
New injectable cancer treatment shows breakthrough efficacy in treatment-resistant cases, with potential global health implications and pharmaceutical market shifts favoring advanced biotechnology.
Escalation Risk
low
Confidence
HIGH
United Kingdom
United States
European Union
Global healthcare systems
11 countries participating in trial
Johnson & Johnson strengthens market position in oncology; UK/EU research institutions gain prestige; potential shift in cancer treatment paradigm from chemotherapy-dependent to targeted immunotherapy approaches; developing nations may face access/affordability challenges for advanced treatments.
Similar to the introduction of monoclonal antibodies (Herceptin, 1998) which revolutionized cancer treatment and reshaped pharmaceutical competition, establishing new standards of care and market dominance.
Lente Económico
📈
Amivantamab injection shows strong efficacy in treatment-resistant head and neck cancer, potentially expanding addressable market for oncology therapeutics and creating new revenue streams for Johnson & Johnson.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical and Biotechnology
Healthcare Services and Hospitals
Medical Devices and Diagnostics
Health Insurance
Patients gain access to effective treatment option with fewer side effects and easier administration (injection vs. intravenous drips), potentially reducing healthcare burden and improving quality of life for treatment-resistant cancer patients and their families.
Regulatory bodies (FDA, EMA) may accelerate approval pathways; healthcare systems must evaluate reimbursement and budget allocation for new oncology treatments; potential for expanded clinical trial requirements; pricing negotiations between governments and pharmaceutical companies likely to intensify.